AIFA is thrilled to announce its partnership with Sanofi for the ‘wear a spot of red for World Allergy Week’ campaign this year (22-28 April 2018).
World Allergy Week is a global campaign of the World Allergy Organisation (WAO) which aims to raise awareness of the impact of allergy in our communities. 2018's focus area is Atopic Dermatitis/Eczema: An Itch that Rashes.
AIFA’s annual campaign sees supporters organise a ‘wear a spot of red’ activity to help raise awareness and funds to support research into allergy.
Sanofi is a global biopharmaceutical company focused on human health and dedicated to supporting people through their health challenges. "Sanofi is proud to support World Allergy Week, with this year’s focus on atopic dermatitis/eczema, a chronic inflammatory allergic disease. Occasions like World Allergy Week are important in raising awareness about this disease which can have devastating effects on patients’ quality of life."
Newborn screening for severe primary immunodeficiency diseases
Doctors are calling for newborn screening to be expanded to include testing for severe forms of primary immunodeficiency diseases, in particular severe combined immunodeficiency or SCID, which, if detected early enough, can be cured by a bone marrow or stem cell transplant.
According to doctors, testing for SCID would significantly improve or even save the lives of affected children.
At present, newborn babies are screened for SCID in New Zealand, most states in the US and many countries throughout Europe, the Middle East and Asia. Doctors hope that Australia will soon follow suit.
This provides one convenient location to see the full range of research supported since 2004.
These research projects cover a wide range of issues in the area of allergy and other immune diseases.
Over the coming months, we hope to provide updates on as many of these projects as possible.
2017 AIFA grant project receives NHMRC funding
We are proud to announce that the 2017 AIFA grant recipient project “A new approach to overcome a childhood autoinflammatory disease” led by Dr Marcia Munoz of the Garvan Institute of Medical Research has received further funding from the National Health & Medical Research Council. This 3-year, $750,000 grant will be a huge boost for this project which could lead to a new treatment for mevalonate kinase deficiency or MKD.
MKD is a lifelong autoinflammatory disease that usually appears in infancy. It is characterised by regular episodes of fever often accompanied by rashes, headaches, joint pain, swollen lymph nodes, vomiting and diarrhea. Current treatments require regular injections, which are expensive, ineffective in many patients, and do not reverse all of the symptoms. New treatments would be a major improvement and have the potential to greatly improve the lives of sufferers.
Congratulations to the team at the Garvan, we look forward to seeing this important project progress.
AIFA Grant submission reminder
AIFA's 2018 research grant EOIs are due 6 April.
There is up to $30,000 in funding available, and applicants need to be associated with a non-profit institution in Australia or New Zealand with the facilities to carry out the research detailed in the application. Previously funded projects include Jack Jumper Ant allergy treatment, understanding FPIES and the AusPollen project.
Allergy and Immunology Foundation of Australasia (AIFA) email@example.com Suite 238, 117 Old Pittwater Road, Brookvale NSW 2100 PO Box 450 Balgowlah NSW 2093 Australia Registered as a charity ABN: 45 615 521 452 All donations are tax deductible
AIFA aims to improve the health of people with allergy and other immune diseases by funding medical research